by Ken Lawless
Volume 4, Issue 1 (January/February 2005)
Canada’s lead in biotechnology, and biotech’s rising influence, is providing a “second chance” at establishing a leading role in the global pharmaceutical industry. Half of all the new drugs approved by FDA are biologics. Why does that equate to a “second chance”? Well, with the skills, knowledge and physical manufacturing processes so completely different from the chemical synthesis of drug manufacture, the global pharma industry is “re-tooling” both its people and its facilities. Canada has the opportunity to leverage its leading biotech position to propel the biopharmaceutical industry forward in the changing landscape…
Citation:
Lawless K. Canadian Biomanufacturing Launches Strategy to Take Advantage of $15 Billion Biopharmaceutical Pipeline: $450 Million Investment Recommended Over Seven Years. BioProcess J, 2005; 4(1): 22-23.